The Medicines Co. (NASDAQ:MDCO) shares traded down 3% during trading on Monday . The company traded as low as $33.57 and last traded at $35.03, with a volume of 390,876 shares changing hands. The stock had previously closed at $36.12.

A number of research analysts recently commented on the stock. Jefferies Group reaffirmed a “buy” rating on shares of The Medicines in a research report on Saturday, May 14th. Leerink Swann reaffirmed a “buy” rating on shares of The Medicines in a research report on Tuesday. Royal Bank Of Canada reaffirmed a “buy” rating on shares of The Medicines in a research report on Tuesday, July 12th. Zacks Investment Research raised shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of The Medicines in a research report on Tuesday, July 12th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The Medicines presently has a consensus rating of “Buy” and an average target price of $46.22.

The company has a 50 day moving average of $35.60 and a 200-day moving average of $34.09. The stock’s market capitalization is $2.40 billion.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Monday, May 9th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.14. The firm had revenue of $50.30 million for the quarter, compared to analyst estimates of $48.96 million. During the same quarter in the prior year, the firm posted $0.08 earnings per share. The company’s quarterly revenue was down 54.3% on a year-over-year basis. On average, equities analysts expect that The Medicines Co. will post ($4.76) earnings per share for the current fiscal year.

In other news, Director Hiroaki Shigeta sold 3,849 shares of the business’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $38.50, for a total transaction of $148,186.50. Following the transaction, the director now directly owns 23,547 shares of the company’s stock, valued at $906,559.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Christopher T. Cox bought 45,985 shares of The Medicines stock in a transaction dated Friday, June 10th. The shares were purchased at an average cost of $37.90 per share, for a total transaction of $1,742,831.50. Following the completion of the transaction, the executive vice president now owns 33,670 shares of the company’s stock, valued at approximately $1,276,093. The disclosure for this purchase can be found here.

A number of hedge funds recently bought and sold shares of MDCO. State of Tennessee Treasury Department bought a new stake in The Medicines during the fourth quarter valued at about $1,945,000. California State Teachers Retirement System boosted its stake in The Medicines by 1.5% in the fourth quarter. California State Teachers Retirement System now owns 122,695 shares of the company’s stock valued at $4,581,000 after buying an additional 1,835 shares in the last quarter. Rhumbline Advisers boosted its stake in The Medicines by 4.7% in the fourth quarter. Rhumbline Advisers now owns 112,120 shares of the company’s stock valued at $4,187,000 after buying an additional 5,080 shares in the last quarter. Marshall Wace LLP bought a new stake in The Medicines during the fourth quarter valued at about $4,677,000. Finally, First Trust Advisors LP bought a new stake in The Medicines during the fourth quarter valued at about $1,715,000.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.